Facing regulatory pressures, resource constraints, and changing health care industry, the medtech industry must redefine innovation to deliver value for payers and patients. Read more.
Pulse of the industry - medical technology report 2013
Cash on prescription 2013
2013 UK Attractiveness Survey
Beyond Borders: global biotech report 2013
Life Sciences deal sentiment scorecard
mHealth: Mobile tech poised to enable new era in health care
Cash on the prescription 2012
Beyond borders: global biotech report 2012
Pharma's $100 billion growth gap
Finding sustainability in biotechnology, pharmaceutical and medical technology
Amplified business decisions are the new norm thanks to rapid changes. From new market entrants and regulatory reform to expiring patents and the growing challenge of chronic diseases, leaders in the life sciences community must explore a new course to address the changing climate for health care — one driven by patients and focused on health outcomes.
Our Global Life Sciences Center brings together a worldwide team of professionals to help you achieve your potential.
We cover key issues in these areas:
Connect with us
Stay connected with us through social media, email alerts or webcasts. Or download our EY Insights app for mobile devices.
How will IFRS 10 and IFRS 11 impact collaboration arrangements in the life sciences industry? We explain.
Have investor-friendly capital allocation and new competitors upended the world order in M&A? Find out how the biopharma sector is facing this challenge.
Here are insights into the role of today's CIO, including an interview with Roche CIO, Werner Boeing.
As big pharma faces a widening growth gap, our Firepower Index highlights industry's capacity for deals in 2013 and beyond.